Navigation Links
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development

-Former GSK Clinical Development Head Brings Over 20 Years of Clinical and

Product Development Expertise to the Company's CNS Portfolio-

RESEARCH TRIANGLE PARK, N.C., June 11 /PRNewswire/ -- CeNeRx BioPharma, Inc., a biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced the appointment of Dr. Mahnaz Asgharnejad as Vice President of Clinical Development. Dr. Asgharnejad will play a central role in expanding CeNeRx's clinical development capabilities and advancing the clinical trials of CeNeRx's investigational drugs. Previously, Dr. Asgharnejad spent more than two decades at GlaxoSmithKline (GSK), where she held clinical development positions of increasing responsibility, most recently as GSK's Senior Director of Psychiatry Clinical Development and Product Strategy.

"Dr. Asgharnejad is a leading CNS clinical development practitioner and we are delighted that she has chosen to join the CeNeRx team," said Daniel Burch, M.D., Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "We expect her proven ability to lead successful clinical development programs addressing a variety of CNS disorders and her deep knowledge of the evolving clinical and regulatory landscape will contribute greatly to our progress going forward."

Dr. Asgharnejad's extensive industry experience includes more than 20 years of clinical program design and management. In recent years, she was responsible for developing and implementing development strategies for candidates at various clinical stages for disorders including unipolar and bipolar depression, ADHD, obesity and migraine. Dr. Asgharnejad has managed projects at all phases of development, including successful new product submissions to the FDA.

"CeNeRx's pipeline of novel candidates for CNS-related disorders with high unmet need presents an exceptional opportunity to leverage my varied expertise in the clinical development of compounds for CNS and other conditions," said Dr. Asgharnejad. "I look forward to working with the CeNeRx team to advance Tyrima(TM), our lead RIMA anti-depressant, into Phase II trials and to supporting the company's promising preclinical portfolio."

Dr. Asgharnejad received B.S. and Pharm.D. degrees from the University of Minnesota. She is a frequent presenter at scientific and medical meetings and is a co-author of several scientific papers.

About CeNeRx BioPharma

CeNeRx (SEN-er-ex) is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compounds, reversible inhibitors of monoamine oxidase, or RIMAs, are in late preclinical and Phase I development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its preclinical pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma and obesity. More information about CeNeRx BioPharma can be found at


GendeLLindheim BioCom Partners

Barbara Lindheim

212 918-4642

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
2. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
3. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
5. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
6. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
7. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
8. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
9. amfAR Appoints Dr. Annette Sohn as Vice President of Global Initiatives
10. Disc Motion Technologies Appoints Industry Veteran as New CEO
11. Setaram Inc. Appoints New CEO/VP
Post Your Comments:
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... substance abuse located in central Michigan, have come together on Thanksgiving Day to ... produced video, available for viewing on the Serenity Point YouTube channel, patients displayed ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record ... performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the ... to rebuild lives and it’s an honor to have served all of these women.” ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology: